Today novonordisk , Denmark based drug maker announced the launch of its new drug for weight management.
liraglutide is GLP-1 agonist , used for treating type II diabetes , approved today as additive to low calories food + physical activity for managing obese people.
GLP-1 receptor agonists, liraglutide stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner. These effects can lead to a reduction of blood glucose.
According to Reuters , the budget for this drug per month per patient is $1,068 which is very high price and I think people who used many many methods for controlling weight or fighting obesity and failed may search for a helper to reduce their weight while they monitoring their calories intake and maintain a physical activity BUT ,
Is the drug really worth $1,068 in term of reducing patient obesity ?
Novo wants to make it blockbuster drug. Blockbuster drugs play an important role in the success of the company specially for a common problem like obesity which demographically increasing with its complication physically or psychologically.